What they found: In normal obese mice: AOD-9604 reduced body fat by 21 % vs placebo, hGH by 24 % The AOD-9604 effect was fully dependent on the 3-adrenergic receptor , in knock-out mice no effect The hGH effect was partly independent of 3-AR , in knock-out mice there was still ~10 % fat reduction AOD-9604 did not raise IGF-1 (control level), whereas hGH raised IGF-1 by 80 % No changes in growth, organ weights (except adipose tissue), fasting insulin Why it matters: The study provided the mechanistic basis for AOD-9604 and confirmed the key business hypothesis: it is possible to separate the lipolytic effect of GH from its growth effect
If you are struggling with your weight, you should explore some of these methods
Reduced Joint Deterioration: Histological analysis in animal studies showed that AOD-9604-treated joints had lower degeneration scores compared to untreated controls
So the defensible position on BPC-157 vs TB-500 is that both show reproducible, mechanistically interesting healing and angiogenic effects in preclinical systems, but neither has demonstrated safety or efficacy in adequately powered human trials
[2] This direct help makes it a top subject for tendon, ligament, and muscle injury studies